Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–42.
Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–96.
Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Target Ther. 2014;7:1015–23.
Davoodi H, Hashemi SR, Seow HF. 5-Fluorouracil induce the expression of TLR4 on HCT116 colorectal cancer cell line expressing different variants of TLR4. Iran J Pharm Res. 2013;12(2):453–60.
Davoodi H, Hashemi SR, Seow HF. Increased NFk-B activity in HCT116 colorectal cancer cell line harboring TLR4 Asp299Gly variant. Iran J Allergy Asthma Immunol. 2012;11(2):121–32.
Nokhandani N, Naghavi Alhosseini M, Memarian A, Davoodi H. Combination of 5-fluorouracil and lipopolysaccharide synergistically induces cytotoxicity and apoptosis in MCF-7 human breast cancer CELLS. Iran J Allergy Asthma Immunol. 2020;19(4):426–36.
Stepaniuk P, Kanani A. Malignancy and immune disorders in patients with hereditary angioedema. Allergy Asthma Clin Immunol. 2021;17(1):134.
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.
Danforth DN. The role of chronic inflammation in the development of breast cancer. Cancers (Basel). 2021;13:3918.
Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.
Medina VA, Martinel D, Brenzoni P, Massari N, Carabajal E, Rivera E. Histamine receptors as potential therapeutic targets for cancer drug development. Drug Dev Case Study Based Insight Mod Strateg. 2011:75–100.
Davio C, Cricco G, Martin G, Fitzsimons C, Bergoc R, Rivera E. Effect of histamine on growth and differentiation of the rat mammary gland. Agent Action. 1994;41:C115–7.
Nicoud MB, Sterle HA, Massari NA, Taquez Delgado MA, Formoso K, Herrero Ducloux MV, et al. Study of the antitumour effects and the modulation of immune response by histamine in breast cancer. Br J Cancer. 2020;122(3):348–60.
Martinel Lamas DJ, Nicoud MB, Sterle HA, Cremaschi GA, Medina VA. Histamine: a potential cytoprotective agent to improve cancer therapy? 2015.
Fritz I, Wagner P, Olsson H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol. 2021;14(4): 101029.
Chen S, Luster AD. Antihistamines for cancer immunotherapy: more than just treating allergies. Cancer Cell. 2022;40(1):9–11.
Massari NA, Nicoud MB, Medina VA. Histamine receptors and cancer pharmacology: an update. Br J Pharmacol. 2020;177(3):516–38.
Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185–96.
Faustino-Rocha AI, Ferreira R, Gama A, Oliveira PA, Ginja M. Antihistamines as promising drugs in cancer therapy. Life Sci. 2017;172:27–41.
Van Schoor J. Antihistamines: a brief review: clinical. Prof Nurs Today. 2012;16(5):16–21.
Ferrara AL, Cristinziano L, Petraroli A, Bova M, Gigliotti MC, Marcella S, et al. Roles of immune cells in hereditary angioedema. Clin Rev Allergy Immunol. 2021;60(3):369–82.
Garcia-Caballero M, Neugebauer E, Rodriguez F, De Castro IN, Vara-Thorbeck C. Histamine synthesis and content in benign and malignant breast tumours. its effects on other host tissues. Surg Oncol. 1994;3:167–73.
Grahn B, Rosengren E. Retardation of protein synthesis in rat tumours on inhibiting histamine formation. Experientia. 1970;26(2):125–6.
Moriarty CM, Stucky JL, Hamburger KW, Patil KD, Foley JF, Koefoot RR. Blood histamine and solid malignant tumors. J Cancer Res Clin Oncol. 1988;114(6):588–92.
Rivera ES, Cricco GP, Engel NI, Fitzsimons CP, Martı́n GA, Bergoc RM. Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Seminars in Cancer Biology. 2000;10(1):15-23.
Martinel Lamas DJ, Croci M, Carabajal E, Crescenti EJV, Sambuco L, Massari NA, et al. Therapeutic potential of histamine H4 receptor agonists in triple-negative human breast cancer experimental model. Br J Pharmacol. 2013;170(1):188–99.
Lamas D, Nicoud MB, Sterle HA, Carabajal E, Tesan F, Perazzo JC, et al. Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell death discov. 2015;1(1):1–11.
Martinel Lamas DJ, Cortina JE, Ventura C, Sterle HA, Valli E, Balestrasse KB, et al. Enhancement of ionizing radiation response by histamine in vitro and in vivo in human breast cancer. Cancer Biol Ther. 2015;16(1):137–48.
Galarza TE, Mohamad NA, Delgado MAT, Vedoya GM, Crescenti EJ, Bergoc RM, et al. Histamine prevents radiation-induced mesenchymal changes in breast cancer cells. Pharmacol Res. 2016;111:731–9.
Akdis C, Blaser K, Akdis M. Genes of tolerance. Allergy. 2004;59(9):897–913.
Leurs R, Church M, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allerg. 2002;32(4):489–98.
Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001;60(5):1133–42.
Fernández-Nogueira P, Bragado P, Almendro V, Ametller E, Rios J, Choudhury S, et al. Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. Oncotarget. 2016;7(5):5313–26.
Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40(36–52):9.
Yang XD, Ai W, Asfaha S, Bhagat G, Friedman RA, Jin G, et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med. 2011;17(1):87–95.
Forward NA, Furlong SJ, Yang Y, Lin TJ, Hoskin DW. Mast cells down-regulate CD4+CD25+ T regulatory cell suppressor function via histamine H1 receptor interaction. J Immunol. 2009;183(5):3014–22.
Leurs R, Smit M, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther. 1995;66(3):413–63.
Dy M, Schneider E. Histamine–cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev. 2004;15(5):393–410.
Eseverri J, Marín A. Proyección de los nuevos antihistamínicos. Allergol Immunopatol. 2000:143–51.
Eseverri J, Marín A. Proyección de los nuevos antihistamínicos. Allergol Immunopatol. 2000:143–51
Davio CA, Cricco GP, Bergoc RM, Rivera ES. H1 and H2 histamine receptors in n-nitroso-N-methylurea (NMU)-induced carcinomas with atypical coupling to signal transducers. Biochem Pharmacol. 1995;50(1):91–6.
Shahid M, Tripathi T, Sobia F, Moin S, Siddiqui M, Khan RA. Histamine, histamine receptors, and their role in immunomodulation: an updated systematic review. Open Immunol J. 2009. https://doi.org/10.2174/1874226200902010009.
Bongers G, Bakker RA, Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol. 2007;73(8):1195–204.
Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jiménez F, Massari N, et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther. 2008;7(1):28–35.
He G-H, Lin J-J, Cai W-K, Xu W-M, Yu Z-P, Yin S-J, et al. Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer. PLoS ONE. 2014;9(5): e97728.
Medina VA, Brenzoni PG, Lamas D, Massari N, Mondillo C, Nunez MA, et al. Role of histamine H4 receptor in breast cancer cell proliferation. Front Biosci (Elite Ed). 2011;3:1042–60.
Nicoud MB, Formoso K, Medina VA. Pathophysiological role of histamine H4 receptor in cancer: therapeutic implications. Front Pharmacol. 2019;10:556.
Speisky D, Táquez Delgado MA, Iotti A, Nicoud MB, Ospital IA, Vigovich F, et al. Histamine H4 Receptor expression in triple-negative breast cancer: an exploratory study. J Histochem Cytochem. 2022;70(4):311–22.
Sterle HA, Nicoud MB, Massari NA, Táquez Delgado MA, Herrero Ducloux MV, Cremaschi GA, et al. Immunomodulatory role of histamine H4 receptor in breast cancer. Br J Cancer. 2019;120(1):128–38.
Cricco G, Valli E, Rivera E, Martín G, Sáez MS, Mohamad N. Histamine and breast cancer: a new role for a well known amine: INTECH Open Access Publisher; 2011.
Singh N, Yadav M, Singh AK, Kumar H, Dwivedi SKD, Mishra JS, et al. Synthetic FXR agonist GW4064 Is a modulator of multiple G protein-coupled receptors. Mol Endocrinol. 2014;28(5):659–73.
Fernandez-Nogueira P, Noguera-Castells A, Fuster G, Recalde-Percaz L, Moragas N, Lopez-Plana A, et al. Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer. Cancer Lett. 2018;424:70–83.
Sterle HA, Nicoud MB, Massari NA, Taquez Delgado MA, Herrero Ducloux MV, Cremaschi GA, et al. Immunomodulatory role of histamine H4 receptor in breast cancer. Br J Cancer. 2019;120(1):128–38.
Rimmer S, Church M. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy. 1990;20:3–17.
Del Cuvillo A, Mullol J, Bartra J, Davila I, Jáuregui I, Montoro J, et al. Comparative pharmacology of the H. J Investig Allergol Clin Immunol. 2006;16(1):3–12.
Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–17.
Horak F, Stübner UP. Comparative tolerability of second generation antihistamines. Drug Saf. 1999;20(5):385–401.
Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V. Cimetidine: an anticancer drug? Eur J Pharm Sci. 2011;42(5):439–44.
Wijtmans M, Leurs R, Esch Id. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert opin investig drug. 2007;16(7):967–85.
Leurs R, Bakker RA, Timmerman H, De Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Disc. 2005;4(2):107–20.
Thurmond RL, Chen B, Dunford PJ, Greenspan AJ, Karlsson L, La D, et al. Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979. J Pharmacol Exp Ther. 2014;349(2):176–84.
Savall BM, Chavez F, Tays K, Dunford PJ, Cowden JM, Hack MD, et al. Discovery and SAR of 6-alkyl-2, 4-diaminopyrimidines as histamine H4 receptor antagonists. J Med Chem. 2014;57(6):2429–39.
Jakhar R, Paul S, Bhardwaj M, Kang SC. Astemizole-histamine induces Beclin-1-independent autophagy by targeting p53-dependent crosstalk between autophagy and apoptosis. Cancer Lett. 2016;372(1):89–100.
García-Quiroz J, García-Becerra R, Barrera D, Santos N, Avila E, Ordaz-Rosado D, et al. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. PLoS ONE. 2012;7(9): e45063.
Fritz I, Wagner P, Broberg P, Einefors R, Olsson H. Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival. Acta Oncol. 2020;59(9):1103–9.
Bens A, Dehlendorff C, Friis S, Cronin-Fenton D, Jensen MB, Ejlertsen B, et al. The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study. Br J Cancer. 2020;122(7):1102–8.
Vila-Leahey A, Oldford SA, Marignani PA, Wang J, Haidl ID, Marshall JS. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016;5(7): e1151591.
Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine inhibition of breast tumor growth is B cell dependent and associated with an enhanced antitumor antibody response. Front Immunol. 2018;9:1894.
Parshad R, Hazrah P, Kumar S, Gupta SD, Ray R, Bal S. Effect of preoperative short-course famotidine on TILs and survival in breast cancer. Indian J Cancer. 2005;42(4):185–90.
Bowrey P, King J, Magarey C, Schwartz P, Marr P, Bolton E, et al. Histamine, mast cells and tumour cell proliferation in breast ncer: does preoperative cimetidine administration have an effect? Br J Cancer. 2000;82(1):167–70.
Mathes RW, Malone KE, Daling JR, Porter PL, Li CI. Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. Cancer Epidemiol Biomark Prev. 2008;17(1):67–72.
Tanaka S, Sakaguchi M, Yoneyama H, Usami Y, Harusawa S. Histamine H3 receptor antagonist OUP-186 attenuates the proliferation of cultured human breast cancer cell lines. Biochem Biophys Res Commun. 2016;480(3):479–85.
García-Quiroz J, González-González ME, Díaz L, Ordaz-Rosado D, Segovia-Mendoza M, Prado-García H, et al. Astemizole, an inhibitor of ether-à-go-go-1 potassium channel, increases the activity of the tyrosine kinase inhibitor gefitinib in breast cancer cellS. Rev Invest Clin. 2019;71(3):186–94.
Aponte-Lopez A, Fuentes-Panana EM, Cortes-Munoz D, Munoz-Cruz S. Mast cell, the neglected member of the tumor microenvironment: role in breast cancer. J Immunol Res. 2018;2018:2584243.
Nicoud MB, Táquez Delgado MA, Sarasola MP, Vidal A, Speisky D, Cremaschi GA, et al. Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model. Cancer Immunol Immunother. 2021;70(1):233–44.